接受tebentafusp治疗的转移性葡萄膜黑色素瘤患者的皮肤毒性:一项回顾性回顾。一个大型专业机构的经验。

IF 2.8 4区 医学 Q1 DERMATOLOGY
Xingyue Maria Wang, Andrew Furness, Kara Heelan
{"title":"接受tebentafusp治疗的转移性葡萄膜黑色素瘤患者的皮肤毒性:一项回顾性回顾。一个大型专业机构的经验。","authors":"Xingyue Maria Wang, Andrew Furness, Kara Heelan","doi":"10.1093/ced/llaf426","DOIUrl":null,"url":null,"abstract":"<p><p>Tebentafusp is a novel T-cell receptor-bispecific protein that targets glycoprotein 100 and CD3. It is the only approved systemic therapy for patients with unresectable or metastatic HLA-A*02:01 positive uveal melanoma. Cutaneous toxicities are common, yet there are limited studies in the literature. We conducted a retrospective observational cohort study of patients with HLA-A*02:01- positive unresectable or metastatic uveal melanoma at our tertiary referral centre, who received tebentafusp therapy from August 2021 to January 2024. Cutaneous toxicity occurred in 89% of patients, but reactions were manageable with no patients permanently discontinuing treatment. To our knowledge, we also report the first case of bullous pemphigoid associated with tebentafusp.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cutaneous toxicities in patients with metastatic uveal melanoma receiving tebentafusp: a retrospective review. The experience of a single large specialist institution.\",\"authors\":\"Xingyue Maria Wang, Andrew Furness, Kara Heelan\",\"doi\":\"10.1093/ced/llaf426\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Tebentafusp is a novel T-cell receptor-bispecific protein that targets glycoprotein 100 and CD3. It is the only approved systemic therapy for patients with unresectable or metastatic HLA-A*02:01 positive uveal melanoma. Cutaneous toxicities are common, yet there are limited studies in the literature. We conducted a retrospective observational cohort study of patients with HLA-A*02:01- positive unresectable or metastatic uveal melanoma at our tertiary referral centre, who received tebentafusp therapy from August 2021 to January 2024. Cutaneous toxicity occurred in 89% of patients, but reactions were manageable with no patients permanently discontinuing treatment. To our knowledge, we also report the first case of bullous pemphigoid associated with tebentafusp.</p>\",\"PeriodicalId\":10324,\"journal\":{\"name\":\"Clinical and Experimental Dermatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ced/llaf426\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ced/llaf426","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

Tebentafusp是一种针对糖蛋白100和CD3的新型t细胞受体双特异性蛋白。它是唯一被批准用于不可切除或转移性HLA-A*02:01阳性葡萄膜黑色素瘤患者的全身疗法。皮肤毒性是常见的,但文献研究有限。我们对三级转诊中心的HLA-A*02:01-阳性不可切除或转移性葡萄膜黑色素瘤患者进行了一项回顾性观察队列研究,这些患者于2021年8月至2024年1月接受了替本他福治疗。89%的患者发生皮肤毒性,但反应是可控的,没有患者永久停止治疗。据我们所知,我们也报告了第一例大疱性类天疱疮与tebentafusp相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cutaneous toxicities in patients with metastatic uveal melanoma receiving tebentafusp: a retrospective review. The experience of a single large specialist institution.

Tebentafusp is a novel T-cell receptor-bispecific protein that targets glycoprotein 100 and CD3. It is the only approved systemic therapy for patients with unresectable or metastatic HLA-A*02:01 positive uveal melanoma. Cutaneous toxicities are common, yet there are limited studies in the literature. We conducted a retrospective observational cohort study of patients with HLA-A*02:01- positive unresectable or metastatic uveal melanoma at our tertiary referral centre, who received tebentafusp therapy from August 2021 to January 2024. Cutaneous toxicity occurred in 89% of patients, but reactions were manageable with no patients permanently discontinuing treatment. To our knowledge, we also report the first case of bullous pemphigoid associated with tebentafusp.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.20
自引率
2.40%
发文量
389
审稿时长
3-8 weeks
期刊介绍: Clinical and Experimental Dermatology (CED) is a unique provider of relevant and educational material for practising clinicians and dermatological researchers. We support continuing professional development (CPD) of dermatology specialists to advance the understanding, management and treatment of skin disease in order to improve patient outcomes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信